Jaguar Animal Health – Net Q2 2025 Revenue Up 35% sequentially

2025 SECOND QUARTER COMPANY FINANCIAL RESULTS:

• Net Prescription Products Revenue: The combined net revenue for the Company’s prescription products (Mytesi^®, Gelclair^®, and Canalevia^®-CA1) was approximately $2.9 million in the second quarter of 2025, representing an increase of approximately 36% over the combined net revenue in the first quarter of 2025, which totaled approximately $2.2 million, and an increase of approximately 10% over the combined net revenue for the second quarter of 2024, which totaled approximately $2.7 million.
• Mytesi Prescription Volume: Mytesi prescription volume increased by approximately 6.5% in the second quarter of 2025 over the first quarter of 2025, and Mytesi prescription volume in the second quarter of 2025 was equal to the volume in the second quarter of 2024. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.

• License Revenue: For the second quarter of 2025, the Company recognized license fees of $42,500 from a securities purchase agreement with a European partner. As of June 30, 2025, the total deferred revenue associated with this contract amounts to approximately $637,500.

• Neonorm^™: Revenues for the non-prescription Neonorm products were minimal for the second quarters of 2025 and 2024.